Transcend Therapeutics

Organization

Transcend Therapeutics is a clinical-stage biotechnology company developing rapid-acting treatments for neuropsychiatric disorders. Its lead investigational candidate, TSND-201 (methylone), is being developed for post-traumatic stress disorder (PTSD) and has received FDA Breakthrough Therapy designation.